This is the protocol for a review and there is no abstract. The objectives are as follows:
The objectives of this review are to:
Compare the relative efficacy of belatacept versus any other immunosuppressive co-intervention for preventing acute rejection and maintaining kidney transplant function, and composite kidney transplant and recipient survival.
Compare the incidence of several adverse events: Post-transplant lymphoproliferative disorder; other malignancies; IF/TA; infective complications; deterioration in blood pressure, lipid and glycaemic control.
Assess any variation in effects by study, intervention and recipient characteristics, including: differences in pre-transplant Epstein-Barr virus status; belatacept dosing regimen; and donor-category (living, standard criteria deceased, or extended criteria deceased).